Advertisement

Coptisine ameliorates renal injury in diabetic rats through the activation of Nrf2 signaling pathway

  • Jiajia Zhai
  • Zeping Li
  • Huifeng Zhang
  • Louyan Ma
  • Zhengquan Ma
  • Yi Zhang
  • Jian Zou
  • Mo Li
  • Li Ma
  • Xiaomiao LiEmail author
Original Article
  • 42 Downloads

Abstract

The present study has been designed and carried out to evaluate the potential of coptisine on diabetic nephropathy. Diabetes was induced in SD rats through one single intraperitoneal injection of streptozotocin (65 mg/kg) method, and then diabetic rats were orally administered with 25 mg/kg/day coptisine or 50 mg/kg/day coptisine for 8 weeks. Severe impairment of renal function in rats with diabetes was observed as indicated by increased urine protein excretion, kidney hypertrophy index, serum creatinine level, and blood urea nitrogen level. Oxidative stress damage was observed as indicated by increased levels of reactive oxygen species, malondialdehyde, and decreased levels of glutathione, superoxide dismutase, and catalase. However, these alterations in kidneys of rats with diabetes were alleviated by administration of coptisine. Furthermore, the expression levels of nuclear factor-erythroid 2-related factor 2 (Nrf2) and its targeted antioxidative genes heme oxygenase 1 and NADPH quinone oxidoreductase 1 in the diabetic kidneys were significantly increased after coptisine treatment. These results suggested that coptisine ameliorated oxidative renal injury in diabetic rats, and the possible mechanisms for the renoprotective effects of coptisine may be related to activation of the Nrf2 signaling pathway.

Keywords

Coptisine Diabetic nephropathy Rat Nrf2 signaling pathway 

Notes

Authors’ contribution

J.J.Z., Z.P.L., and X.M.L. conceived and designed the research.

H.F.Z., L.Y.M., Z.Q.M., and Y.Z. conducted experiments.

J.Z., M.L., and L.M. analyzed data.

J.J.Z. and Z.P.L. prepared the manuscript.

H.F.Z. and L.Y.M. administrated the project.

X.M.L. revised the manuscript.

All authors read and approved the final version of the manuscript.

Funding

This study was supported by a grant from the National Natural Science Foundation of China (no. 81573746).

Compliance with ethical standards

All animal procedures in this work were conducted according to the Animal Ethics Committee at the First Affiliated Hospital of Air Force Medical University.

Conflict of interest

The authors declare that they have no conflicts of interest.

References

  1. Ali T, Kim T, Rehman SU, Khan MS, Amin FU, Khan M, Ikram M, Kim MO (2018) Natural dietary supplementation of anthocyanins via PI3K/Akt/Nrf2/HO-1 pathways mitigate oxidative stress, neurodegeneration, and memory impairment in a mouse model of Alzheimer’s disease. Mol Neurobiol 55:6076–6093CrossRefPubMedGoogle Scholar
  2. Aouacheri O, Saka S, Krim M, Messaadia A, Maidi I (2015) The investigation of the oxidative stress-related parameters in type 2 diabetes mellitus. Can J Diabetes 39:44–49CrossRefPubMedGoogle Scholar
  3. Arora MK, Singh UK (2014) Oxidative stress: meeting multiple targets in pathogenesis of diabetic nephropathy. Curr Drug Targets 15:531–538CrossRefPubMedGoogle Scholar
  4. Baldissera MD, Goncalves RA, Sagrillo MR, Grando TH, Ritter CS, Grotto FS, Brum GF, da Luz SC, Silveira SO, Fausto VP, Boligon AA, Vaucher RA, Stefani LM, da Silva AS, Souza CF, Monteiro SG (2016) Effects of treatment with the anti-parasitic drug diminazene aceturate on antioxidant enzymes in rat liver and kidney. Naunyn Schmiedeberg's Arch Pharmacol 389:429–438CrossRefGoogle Scholar
  5. Calabrese V, Cornelius C, Leso V, Trovato-Salinaro A, Ventimiglia B, Cavallaro M, Scuto M, Rizza S, Zanoli L, Neri S, Castellino P (2012) Oxidative stress, glutathione status, sirtuin and cellular stress response in type 2 diabetes. Biochim Biophys Acta 1822:729–736CrossRefPubMedGoogle Scholar
  6. Chai FN, Ma WY, Zhang J, Xu HS, Li YF, Zhou QD, Li XG, Ye XL (2018) Coptisine from Rhizoma coptidis exerts an anti-cancer effect on hepatocellular carcinoma by up-regulating miR-122. Biomed Pharmacother 103:1002–1011CrossRefPubMedGoogle Scholar
  7. Chen HB, Luo CD, Liang JL, Zhang ZB, Lin GS, Wu JZ, Li CL, Tan LH, Yang XB, Su ZR, Xie JH, Zeng HF (2017) Anti-inflammatory activity of coptisine free base in mice through inhibition of NF-kappaB and MAPK signaling pathways. Eur J Pharmacol 811:222–231CrossRefPubMedGoogle Scholar
  8. Cho NH, Shaw JE, Karuranga S, Huang Y, da Rocha Fernandes JD, Ohlrogge AW, Malanda B (2018) IDF diabetes atlas: global estimates of diabetes prevalence for 2017 and projections for 2045. Diabetes Res Clin Pract 138:271–281CrossRefGoogle Scholar
  9. Friedemann T, Schumacher U, Tao Y, Leung AK, Schroder S (2015) Neuroprotective activity of coptisine from Coptis chinensis (Franch). Evidence Based Complement Alternat Med 2015:827308CrossRefGoogle Scholar
  10. Gong LL, Fang LH, Wang SB, Sun JL, Qin HL, Li XX, Wang SB, Du GH (2012) Coptisine exert cardioprotective effect through anti-oxidative and inhibition of RhoA/rho kinase pathway on isoproterenol-induced myocardial infarction in rats. Atherosclerosis 222:50–58CrossRefPubMedGoogle Scholar
  11. He L, Li P, Yu LH, Li L, Zhang Y, Guo Y, Long M, He JB, Yang SH (2018) Protective effects of proanthocyanidins against cadmium-induced testicular injury through the modification of Nrf2-Keap1 signal path in rats. Environ Toxicol Pharmacol 57:1–8CrossRefPubMedGoogle Scholar
  12. Hu YR, Ma H, Zou ZY, He K, Xiao YB, Wang Y, Feng M, Ye XL, Li XG (2017) Activation of Akt and JNK/Nrf2/NQO1 pathway contributes to the protective effect of coptisine against AAPH-induced oxidative stress. Biomed Pharmacother 85:313–322CrossRefPubMedGoogle Scholar
  13. Ishii T, Itoh K, Yamamoto M (2002) Roles of Nrf2 in activation of antioxidant enzyme genes via antioxidant responsive elements. Methods Enzymol 348:182–190CrossRefPubMedGoogle Scholar
  14. Jiang T, Huang Z, Lin Y, Zhang Z, Fang D, Zhang DD (2010) The protective role of Nrf2 in streptozotocin-induced diabetic nephropathy. Diabetes 59:850–860CrossRefPubMedPubMedCentralGoogle Scholar
  15. Jung HA, Yoon NY, Bae HJ, Min BS, Choi JS (2008) Inhibitory activities of the alkaloids from Coptidis Rhizoma against aldose reductase. Arch Pharm Res 31:1405–1412CrossRefPubMedGoogle Scholar
  16. Jung HA, Min BS, Yokozawa T, Lee JH, Kim YS, Choi JS (2009) Anti-Alzheimer and antioxidant activities of Coptidis Rhizoma alkaloids. Biol Pharm Bull 32:1433–1438CrossRefPubMedGoogle Scholar
  17. Lai XR, Zhou BH, Du MS, Zheng HJ, Geng ZP, Li JC, Meng XL, Zhang Y, Zhang J (2016) [determination of six alkaloids in six types of Coptidis Rhizoma pieces by RP-HPLC and spectrum–effect relationships with anti-diabetes pharmacodynamics data]. Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi =. China J Chin Mater Med 41:4579–4586Google Scholar
  18. Lima AL, Illing T, Schliemann S, Elsner P (2017) Cutaneous manifestations of diabetes mellitus: a review. Am J Clin Dermatol 18:541–553CrossRefPubMedGoogle Scholar
  19. Liu F, Xie M, Chen D, Li J, Ding W (2013) Effect of V (IV) O (dipic-cl)(H2O)2 on lipid metabolism disorders in the liver of STZ-induced diabetic rats. J Diabetes Res 2013:956737PubMedPubMedCentralGoogle Scholar
  20. Meng FC, Wu ZF, Yin ZQ, Lin LG, Wang R, Zhang QW (2018) Coptidis rhizoma and its main bioactive components: recent advances in chemical investigation, quality evaluation and pharmacological activity. 13:13Google Scholar
  21. Miranda-Diaz AG, Pazarin-Villasenor L (2016) Oxidative stress in diabetic nephropathy with early chronic kidney disease. 2016:7047238Google Scholar
  22. Pyo MC, Yang SY, Chun SH, Oh NS, Lee KW (2016) Protective effects of Maillard reaction products of whey protein concentrate against oxidative stress through an Nrf2-dependent pathway in HepG2 cells. Biol Pharm Bull 39:1437–1447CrossRefPubMedGoogle Scholar
  23. Rossing P (2006) Diabetic nephropathy: worldwide epidemic and effects of current treatment on natural history. Curr Diabetes Rep 6:479–483CrossRefGoogle Scholar
  24. Schieber M, Chandel NS (2014) ROS function in redox signaling and oxidative stress. Curr Biol: CB 24:R453–R462CrossRefPubMedGoogle Scholar
  25. Sykiotis GP, Habeos IG, Samuelson AV, Bohmann D (2011) The role of the antioxidant and longevity-promoting Nrf2 pathway in metabolic regulation. Curr Opin Clin Nutr Metab Care 14:41–48CrossRefPubMedPubMedCentralGoogle Scholar
  26. Uruno A, Furusawa Y, Yagishita Y, Fukutomi T, Muramatsu H, Negishi T, Sugawara A, Kensler TW, Yamamoto M (2013) The Keap1–Nrf2 system prevents onset of diabetes mellitus. Mol Cell Biol 33:2996–3010CrossRefPubMedPubMedCentralGoogle Scholar
  27. Wei S, Zhang M, Yu Y, Lan X, Yao F, Yan X, Chen L, Hatch GM (2016) Berberine attenuates development of the hepatic gluconeogenesis and lipid metabolism disorder in type 2 diabetic mice and in palmitate-incubated HepG2 cells through suppression of the HNF-4alpha miR122 pathway. PLoS One 11:e0152097CrossRefPubMedPubMedCentralGoogle Scholar
  28. Wu D, Wen W, Qi CL, Zhao RX, Lu JH, Zhong CY, Chen YY (2012) Ameliorative effect of berberine on renal damage in rats with diabetes induced by high-fat diet and streptozotocin. Phytomedicine 19:712–718CrossRefPubMedGoogle Scholar
  29. Wu JS, Liu Y, Shi R, Lu X, Ma YM, Cheng NN (2014) Effects of combinations of Xiexin decoction constituents on diabetic nephropathy in rats. J Ethnopharmacol 157:126–133CrossRefPubMedGoogle Scholar
  30. Yokozawa T, Ishida A, Kashiwada Y, Cho EJ, Kim HY, Ikeshiro Y (2004) Coptidis Rhizoma: protective effects against peroxynitrite-induced oxidative damage and elucidation of its active components. J Pharm Pharmacol 56:547–556CrossRefPubMedGoogle Scholar
  31. Zhou H, Jiang T, Wang Z, Ren S, Zhao X, Wu W, Jiang L, Liu Z, Teng L (2014) Screening for potential -alpha -glucosidase inhibitors in Coptis chinensis franch extract using ultrafiltration LC-ESI-MSn. Pak J Pharm Sci 27:2007–2012PubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of Endocrinology, Xijing HospitalAir Force Medical UniversityXi’anPeople’s Republic of China
  2. 2.Department of GeratologyXi’an Ninth HospitalXi’anPeople’s Republic of China
  3. 3.Department of Clinical Medicine, School of Queen MaryNanchang UniversityNanchangPeople’s Republic of China
  4. 4.Department of NeurologyXi’an Electric Power Central HospitalXi’anPeople’s Republic of China
  5. 5.Department of EndocrinologyXi’an Ninth HospitalXi’anPeople’s Republic of China
  6. 6.Department of Internal Medicine522nd Hospital of Chinese PLALuoyangPeople’s Republic of China

Personalised recommendations